In The News: School of Integrated Health Sciences

Streetwise Reports

Biopharmaceutical company Axsome Therapeutics Inc. (AXSM:NASDAQ), which is focused on developing new medicines for use in the treatment of central nervous system (CNS) disorders, today announced that "AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the ACCORD (Assessing Clinical Outcomes in Alzheimer's Disease Agitation) Phase 3 trial, by substantially and statistically significantly delaying the time to relapse and preventing relapse of agitation in patients with Alzheimer's disease, as compared to placebo."

Neurology Live

Newly announced findings from the phase 3 ACCORD trial (NCT04797715) showed that AXS-05 (Axsome Therapeutics), a novel, investigational n-methyl-D-aspartate (NMDA) receptor antagonist, met its primary end point of statistically significant delay in time to relapse and preventing relapse of agitation in patients with Alzheimer disease (AD) agitation.1

Women's Health

Diet trends go in and out of style, but intermittent fasting has been a buzzy diet among celebs for a while. Plenty of people swear by the health and weight loss benefits. Still, even the same weight-loss method can work differently from person to person, you may be wondering whether there is a best way to do intermittent fasting for women and get the most out of your efforts.

Healthline

A new study that is being presented this week at the American College of Cardiology Middle East 2022 Together With the 13th Emirates Cardiac Society Congress, reports that eating more refined grains was linked with a greater risk for premature coronary artery disease (PCAD).

Healthline

According to a new study published this month in the Journal of Affective Disorders, vegetarians experienced depressive episodes twice as often as those who ate meat.

Voice of America

Drugmakers Biogen and Eisai say their experimental drug lecanemab slowed the progress of Alzheimer’s disease in a large human study the companies did.

KLAS-TV: 8 News Now

As far as UNLV students go, she was older, in her 30s. McKenzie Mayor remembers sensing despair. The woman likely had lost her job, money was tight, Mayor thought.

Reuters

An experimental Alzheimer's drug made by Eisai Co Ltd (4523.T) and Biogen (BIIB.O) slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.

U.S. News & World Report

An experimental Alzheimer's drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.

Science Daily

There are more than two million people living with an amputation in the United States, with about 400 being added daily. For many of them, prostheses or artificial limbs are a part of their lives, and they need to relearn how their bodies move with their new limbs all over again.

Newswise

There are more than two million people living with an amputation in the United States, with about 400 being added daily. For many of them, prostheses or artificial limbs are a part of their lives, and they need to relearn how their bodies move with their new limbs all over again.

KNPR News

Running can lead to a lot of injuries. So how can a runner remain fit while they heal?